WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Transplant Product Efficacy Framework v16b, Diagnosis documents Hypertension, Graft Loss defined by following options Graft Nephrectomy, Solid Organ Transplant has occurence (1...n) Yes, Glomerular Filtration Rate (GFR) is measured as decreased, Recipient Characteritics documents Dialysis, Recipient Characteritics documents Panel Reactive Antibody, Clinically Suspected Acute Rejection (CSAR) recorded in Date of CSAR, Viral Status can be assessed at defined time points, Therapeutic Efficacy Point is the intersection of Therapeutic Intervention, Graft Loss is recorded at Date of Graft Loss, Biopsy Result has option T Cell Mediated Rejection, Biopsy Proven Acute Rejection (BPAR) is observed on Date of Biopsy, Body Suface Area (BSA) is derived from Weight, Biopsy Result has option Antibody Mediated Rejection, Cause of Death has option PTLD (post-transplant lymphoproliferative disorder), Observation or Assessment is used to monitor the effectiveness of Therapeutic Intervention, Serum Creatinine (SCr) is measured as increased, Deceased has option Expanded Criteria Donor (ECD), Donor Characteristics documents Serum Creatinine (SRc), Acute Rejection has pre-condition Clinically Suspected Acute Rejection (CSAR)